Trial Profile

A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use
Acronyms CHARLI

Most Recent Events

06 Jun 2023 Results (n=27) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
06 Apr 2022 Status changed from recruiting to active, no longer recruiting.
23 Mar 2021 Planned End Date changed from 30 Jun 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com